Cardioloxía
Servicio
Wrocław Medical University
Breslavia, PoloniaPublicacións en colaboración con investigadores/as de Wrocław Medical University (7)
2022
-
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520
2021
-
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116
-
Empagliflozin in heart failure with a preserved ejection fraction
New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461
2020
-
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392
-
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171
2018
-
Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology
European Journal of Heart Failure, Vol. 20, Núm. 1, pp. 3-15
2017
-
Cardiovascular efficacy and safety of bococizumab in high-risk patients
New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539